Ben Carpenter, MD, PhD - Exploring Novel Therapeutic Frontiers in Transfusion-Dependent Beta Thalassemia: The Path to Transfusion Independence

episode

CME in Minutes: Education in Oncology & Hematology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Full Show Podcast: 23 September 2026 1h 29m · 22 Sep 2026 · The Mike Hosking Breakfast

Evening Wire: Trump Delivers Remarks to the UN & Nolan Wells Drowning Updates | 9.22.26 11 min · 22 Sep 2026 · Morning Wire

Willie Robertson Wouldn’t Let His Kids Open Their Own Gifts | Duck Call Room #589 59 min · 22 Sep 2026 · Duck Call Room

🎙Tell us your Group Chat Names - The Chat 10 min · 22 Sep 2026 · The Hauraki Breakfast Podcast

MORNING TEA: Taylor Swift's Surprise New Single & William and Kate Hit The Red Carpet With Tom Cruise 7 min · 22 Sep 2026 · The Spill

Trump Touts Foreign Policy Vision in UN Speech Ahead of Midterms 13 min · 22 Sep 2026 · WSJ What’s News

Report any issue

Source

Recorded25 Jun 2024

Publisherc.answersincme.com ↗

Handlerec:766035

Show notes

Please visit answersincme.com/VMK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology discusses the use of novel therapies for patients with transfusion-dependent beta thalassemia. Upon completion of this activity, participants should be better able to: Describe the limitations of ongoing transfusions for patients with transfusion-dependent beta thalassemia (TDT); Review the evidence on novel therapies for TDT; and Outline shared decision-making strategies for the potential use of novel therapies for patients with TDT.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in